血管扩张剂负荷心脏磁共振成像的预后价值:多中心48 000患者年随访研究
结果显示负荷CMR异常与全因死亡率独立相关,且能改善风险预测与重分类,在有无冠心病史及不同左心室射血分数亚组中均一致。
要点
- 负荷CMR异常与全因死亡率独立相关(HR 1.883,95%CI 1.680-2.112)。
- 加入负荷CMR可改善两种风险模型对死亡率的预测与风险重分类。
- 关联在有无冠心病史及正常或异常左心室射血分数亚组中均显著。
核心结论
- 临床血管扩张剂负荷CMR与已知或疑似冠心病患者全因死亡率相关,且在多个亚组中一致。
主要发现
- 9151例中4408例负荷CMR正常、4743例异常,随访期间1517例死亡。
- 多变量分析中,加入负荷CMR改善模型1死亡率预测(HR 1.83,95%CI 1.63-2.06,P<.001)。
- 加入负荷CMR改善模型2死亡率预测(HR 1.80,95%CI 1.60-2.03,P<.001),风险重分类净改善11.4%(95%CI 7.3-13.6,P<.001)。
- 校正年龄、性别及心脏危险因素后,负荷CMR异常与全因死亡率相关(HR 1.883,95%CI 1.680-2.112,P<.001)。
临床怎么用
- 对已知或疑似冠心病患者,可将血管扩张剂负荷CMR结果纳入死亡风险分层。
- 负荷CMR异常提示死亡风险升高,应结合临床加强随访与管理。
局限性
- 原文未报告研究局限性相关内容。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Stress cardiac magnetic resonance imaging (CMR) is not widely used in current clinical practice, and its ability to predict patient mortality is unknown. OBJECTIVE: To determine whether stress CMR is associated with patient mortality. DESIGN, SETTING, AND PARTICIPANTS: Real-world evidence from consecutive clinically ordered CMR examinations. Multicenter study of patients undergoing clinical evaluation of myocardial ischemia. Patients with known or suspected coronary artery disease (CAD) underwent clinical vasodilator stress CMR at 7 different hospitals. An automated process collected data from the finalized clinical reports, deidentified and aggregated the data, and assessed mortality using the US Social Security Death Index. MAIN OUTCOMES AND MEASURES: All-cause patient mortality. RESULTS: Of the 9151 patients, the median (interquartile range) patient age was 63 (51-70) years, 55% were men, and the median (interquartile range) body mass index was 29 (25-33) (calculated as weight in kilograms divided by height in meters squared). The multicenter automated process yielded 9151 consecutive patients undergoing stress CMR, with 48 615 patient-years of follow-up. Of these patients, 4408 had a normal stress CMR examination, 4743 had an abnormal examination, and 1517 died during a median follow-up time of 5.0 years. Using multivariable analysis, addition of stress CMR improved prediction of mortality in 2 different risk models (model 1 hazard ratio [HR], 1.83; 95% CI, 1.63-2.06; P < .001; model 2: HR, 1.80; 95% CI, 1.60-2.03; P < .001) and also improved risk reclassification (net improvement: 11.4%; 95% CI, 7.3-13.6; P < .001). After adjustment for patient age, sex, and cardiac risk factors, Kaplan-Meier survival analysis showed a strong association between an abnormal stress CMR and mortality in all patients (HR, 1.883; 95% CI, 1.680-2.112; P < .001), patients with (HR, 1.955; 95% CI, 1.712-2.233; P < .001) and without (HR, 1.578; 95% CI, 1.235-2.2018; P < .001) a history of CAD, and patients with normal (HR, 1.385; 95% CI, 1.194-1.606; P < .001) and abnormal left ventricular ejection fraction (HR, 1.836; 95% CI, 1.299-2.594; P < .001). CONCLUSIONS AND RELEVANCE: Clinical vasodilator stress CMR is associated with patient mortality in a large, diverse population of patients with known or suspected CAD as well as in multiple subpopulations defined by history of CAD and left ventricular ejection fraction. These findings provide a foundational motivation to study the comparative effectiveness of stress CMR against other modalities.
引用
- Heitner JF, Kim RJ, Kim HW, et al. Prognostic Value of Vasodilator Stress Cardiac Magnetic Resonance Imaging: A Multicenter Study With 48 000 Patient-Years of Follow-up. JAMA Cardiol. 2019. PMID: 30735566. doi:10.1001/jamacardio.2019.0035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。